Article
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2021
Pappa Theodora, Ahmadi Sara, Marqusee Ellen, Johnson Hannah L, Nehs Matthew A, Cho Nancy L, Barletta Justine A, Lorch Jochen H, Doherty Gerard M, Lindeman Neal I, Alexander Erik K, Landa Iñigo
Abstract excerpt
PURPOSE: The extent to which routine genomic sequencing can identify relevant secondary genomic alterations among BRAFV600E -mutant papillary thyroid carcinoma (PTC) is unknown. Such markers would prove highly valuable for prognostic purposes. EXPERIMENTAL DESIGN: We reviewed clinicopathologic data of 225 patients with BRAFV600E -mutant PTC and integrated them with genomic data derived from targeted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
